Amneal/Mallinckrodt Enter Buprenorphine+Naloxone Distribution Agreement

Mallinckrodt has entered into an agreement with Amneal Pharmaceuticals to distribute to addiction treatment centres Mallinckrodt's buprenorphine hydrochloride and naloxone hydrochloride dihydrate sublingual tablets (CIII), a generic version of Reckitt Benckiser's Suboxone. The product is manufactured in Amneal's Hauppauge, NY, facility. It is a prescription medication indicated for the maintenance treatment of opioid dependence. The contract covers a period of three years, with an option to extend.

Mallinckrodt commented that it was a major supplier of generic opioid dependence products to US addiction treatment centres. The collaboration is the first between Mallinckrodt and Amneal and covers both the 8mg/2mg and 2mg/0.5mg dosage strengths of buprenorphine+naloxone. Mallinckrodt's version was approved by the FDA on February 22 2013; to date only two generic versions have been approved, with the other belonging to Actavis. This was approved on the same day as Mallinckrodt's.



Mallinckrodt has entered into an agreement with Amneal Pharmaceuticals to distribute to addiction treatment centres Mallinckrodt's buprenorphine hydrochloride and naloxone hydrochloride dihydrate sublingual tablets (CIII), a generic version of Reckitt Benckiser's Suboxone. The product is manufactured in Amneal's Hauppauge, NY, facility. It is a prescription medication indicated for the maintenance treatment of opioid dependence. The contract covers a period of three years, with an option to extend.

Mallinckrodt commented that it was a major supplier of generic opioid dependence products to US addiction treatment centres. The collaboration is the first between Mallinckrodt and Amneal and covers both the 8mg/2mg and 2mg/0.5mg dosage strengths of buprenorphine+naloxone. Mallinckrodt's version was approved by the FDA on February 22 2013; to date only two generic versions have been approved, with the other belonging to Actavis. This was approved on the same day as Mallinckrodt's.



Agreement Information:
Agreement Status: New Date Announced: 20 Aug 2013
Date Last Reported: Duration:
Est Total Value: Investment To Date:
Agreement Type: Distribution
Generic / Brand Name: buprenorphine naloxone Suboxone
Therapeutic Area: Central Nervous System
Indication: Drug abuse Addiction
Techonology/Field: N/A
This article is tagged to:
Sector: Pharmaceuticals & Healthcare, Medical Devices
Geography: United States
×

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.